The transition from batch to continuous manufacturing for tablet manufacturing – performance comparison and control system review
- 1 Imperial College London
* Author to whom correspondence should be addressed.
Abstract
The pharmaceutical industry is motivated to improve tablet productivity in order to adapt to the expanding drug market. One innovative way is the transition of the traditional batch tablet manufacturing process to a continuous process. This paper aims to review the performance of continuous tablet manufacturing processes. From the comparison of continuous to traditional batch processes, the continuous tablet manufacturing process demonstrates improvements in production flexibility, robustness, and ultimately process profitability. The continuous process is proven to mix drug particles with more evenly distributed size and less segregation resulting in tablets with better quality compared to the traditional batch process. The improvement on the continuous tablet manufacturing process requires robust control system for process automation to counteract process noise and disturbances in process feed. A well-tuned Proportional Integral Derivative (PID) control is sufficient for the process to produce a desirable product. Developing a new algorithm for model predictive control (MPC) and enhancing the control system with MPC-PID control can further improve the system performance. Overall, the transition from batch to continuous tablet manufacturing is supported by pharmaceutical companies as well as organizations like Food and Drug Administration (FDA).
Keywords
batch, continuous, tablet manufacturing, process control
[1]. D. Ross, “Continuous Tablet Manufacturing: Faster Development and Greater Efficiency,” Sep. 2014. [Online]. Available: https://tabletscapsules.com/wp-content/uploads/pdf/tc_20140901_0018.pdf. [Accessed 12 Nov. 2021].
[2]. Z. Brennan, “FDA Allows First Switch From Batch to Continuous Manufacturing for HIV Drug,” 2016. [Online]. Available: https://www.raps.org/regulatory-focus%E2%84%A2/news-articles/2016/4/fda-allows-first-switch-from-batch-to-continuous-manufacturing-for-hiv-drug. [Accessed 12 Nov. 2021].
[3]. S. L. Lee, T. F. O’Connor, X. Yang, C. N. Cruz, S. Chatterjee, R. D. Madurawe, C. M. V. Moore, L. X. Yu and J. Woodcock, “Modernizing Pharmaceutical Manufacturing: from Batch to Continuous Production,” Journal of Pharmaceutical Innovation, vol. 10, no. 3, pp. 191-199, 2015.
[4]. S. S. Stephen McCarthy, “Converting to a “Batch-less” World: Quality Implications of Continuous Manufacturing,” 26 Mar 2019. [Online]. Available: https://www.pharmaceuticalprocessingworld.com/converting-to-a-batch-less-world-quality-implications-of-continuous-manufacturing/.
[5]. X. Xie and R. Schenkendorf, “Robust Process Design in Pharmaceutical Manufacturing under Batch-to-Batch Variation,” Processes, vol. 7, no. 8, p. 509, 2019.
[6]. G. Betz, P. Junker-Bürgin and H. Leuenberger, “Batch And Continuous Processing In The Production Of Pharmaceutical Granules,” Pharmaceutical Development and Technology, vol. 8, no. 3, pp. 289-297, 2003.
[7]. A.-P. Karttunena, H. Wikströmb, P. Tajarobib, M. Franssonb, A. Sparén, M. Maruccib, J. Ketolainena, S. Folestadb, O. Korhonena and S. Abrahmsén-Alami, “Comparison between integrated continuous direct compression line and batch processing – The effect of raw material properties,” European Journal of Pharmaceutical Sciences, vol. 133, pp. 40-53, 2019.
[8]. K. Matsunamia, T. Nagatob, K. Hasegawab and H. Sugiyamaa, “A large-scale experimental comparison of batch and continuous technologies in pharmaceutical tablet manufacturing using ethenzamide,” International Journal of Pharmaceutics, vol. 559, pp. 210-219, 2019.
[9]. S. D. Schaber, D. I. Gerogiorgis, R. Ramachandran, J. M. B. Evans, P. I. Barton and B. L. Trout, “Economic Analysis of Integrated Continuous and Batch Pharmaceutical Manufacturing: A Case Study,” Industrial & Engineering Chemistry Research, vol. 50, no. 17, pp. 10083-10092, 2011.
[10]. C. V. Rossi, “A Comparative Investment Analysis of Batch Versus Continuous Pharmaceutical Manufacturing Technologies,” Journal of Pharmaceutical Innovation, 2022.
[11]. C. J. Testa, C. Hu, K. Shvedova, W. Wu, R. Sayin, F. Casati, B. S. Halkude, P. Hermant, D. E. Shen, A. Ramnath, Q. Su, S. C. Born, B. Takizawa, S. Chattopadhyay, T. F. O’Connor, X. Yang, S. Ramanujam and S. Mascia, “Design and Commercialization of an End-to-End Continuous Pharmaceutical Production Process: A Pilot Plant Case Study,” Organic Process Research & Development, vol. 24, no. 12, pp. 2874-2889, 2020.
[12]. M. M. Nasr, M. Krumme, Y. Matsuda, B. L. Trout, C. Badman, S. Mascia, C. L. Cooney, K. D. Jensen, A. Florence, C. Johnston, K. Konstantinov and S. L. Lee, “Regulatory Perspectives on Continuous Pharmaceutical Manufacturing: Moving From Theory to Practice,” Journal of Pharmaceutical Sciences, vol. 106, no. 11, pp. 3199-3206, 2017.
[13]. L. X. Yu, G. Amidon, M. A. Khan, S. W. Hoag, J. Polli, G. K. Raju and a. J. Woodcock, “Understanding Pharmaceutical Quality by Design,” The AAPS Journal, vol. 16, no. 4, pp. 771-783, 2014.
[14]. D. Malevez and D. Copot, “From batch to continuous tablet manufacturing: a control perspective,” IFAC-PapersOnLine, vol. 54, no. 15, pp. 562-567, 2021.
[15]. A. Mesbah, J. A. Paulson, R. Lakerveld and R. D. Braatz, “Model Predictive Control of an Integrated Continuous Pharmaceutical Manufacturing Pilot Plant,” Organic Process Research & Development, vol. 21, no. 6, pp. 844-854, 2017.
[16]. J. Rehrl, J. Kruis, S. S. J. Khinast and M. Horn, “Optimized continuous pharmaceutical manufacturing via model-predictive control,” International Journal of Pharmaceutics, vol. 510, no. 1, pp. 100-115, 2016.
[17]. W. Wong, E. Chee, J. Li and X. Wang, “Recurrent Neural Network-Based Model Predictive Control for Continuous Pharmaceutical Manufacturing,” Mathematics, vol. 6, no. 11, p. 242, 2018.
[18]. A. S. MYERSON, M. KRUMME, M. NASR, H. THOMAS and R. D. BRAATZ, “Control Systems Engineering in Continuous Pharmaceutical Manufacturing May 20–21, 2014 Continuous Manufacturing Symposium,” Journal of Pharmaceutical Sciences, vol. 104, no. 3, pp. 832-839, 2015.
[19]. W. Engisch and F. Muzzio, “Using Residence Time Distributions (RTDs) to Address the Traceability of Raw Materials in Continuous Pharmaceutical Manufacturing,” Journal of Pharmaceutical Innovation, vol. 11, no. 1, pp. 64-81, 2015.
[20]. C. Liew, A. Karande and P. Heng, “In-line quantification of drug and excipients in cohesive powder blends by near infrared spectroscopy,” International Journal of Pharmaceutics, vol. 386, no. 1-2, pp. 138-148, 2010.
[21]. K. P. Cole and M. D. Johnson, “Continuous flow technology vs. the batch-by-batch approach to produce pharmaceutical compounds,” Expert Review of Clinical Pharmacology, vol. 11, no. 1, pp. 5-13, 2017.
[22]. V. Barba, “Pfizer’s ‘long and complex’ journey to continuous manufacturing,” 2019. [Online]. Available: https://www.outsourcing-pharma.com/Article/2019/11/27/Pfizer-executive-at-Pharma-Integrates-on-continuous-manufacturing. [Accessed 05 07 2022].
[23]. F. Kansteiner, “End-to-end: Can pharma finally make the dream of continuous manufacturing a reality?,” 2021. [Online]. Available: https://www.fiercepharma.com/manufacturing/end-to-end-how-pharma-making-dream-continuous-manufacturing-a-reality. [Accessed 05 07 2022]
Cite this article
Gao,R. (2023). The transition from batch to continuous manufacturing for tablet manufacturing – performance comparison and control system review. Applied and Computational Engineering,7,685-691.
Data availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
Disclaimer/Publisher's Note
The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
About volume
Volume title: Proceedings of the 3rd International Conference on Materials Chemistry and Environmental Engineering (CONF-MCEE 2023), Part II
© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and
conditions of the Creative Commons Attribution (CC BY) license. Authors who
publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons
Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this
series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published
version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial
publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and
during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See
Open access policy for details).